David Barrett
Head, Engineered Small Molecules (ESM), Oncology Research Astellas Pharma
Seminars
Tuesday 28th October 2025
Targeting ‘Undruggable’ Targets: Pioneering Novel Applications of Heterobifunctional Degraders – An Update
11:45 am
